Quantitation of autoantibodies in systemic autoimmune diseases: Clinically useful?

Lupus

Volumn 15, Issue 7, 2006, Pages 397-402

  Kallenberg, C G M ^a   Stegeman, C A ^a   Bootsma, H ^a   Bijl, M ^a   Limburg, P C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anti dsDNA; Anti neutrophil cytoplasmic antibodies; PR3 ANCA; Relapse; SLE; Wegener's Granulomatosis

Indexed keywords

ABETIMUS; AUTOANTIBODY; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; RECOMBINANT DNA;

ANCA ASSOCIATED VASCULITIS; ARTICLE; AUTOIMMUNE DISEASE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; RISK FACTOR; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOIMMUNE DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RADIOIMMUNOPRECIPITATION ASSAY; RECURRENCE;

EID: 33746583997     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203306lu2323oa     Document Type: Article

References (51)

1. Wiik AS. Anti-nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases. Scand J Rheumatol 2005; 34: 260-268.
2. Kallenberg CGM, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon. Ann Rheum Dis 1988; 47: 634-641.
3. Coremans IE, Spronk PE, Bootsma H et al. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis 1995; 26: 595-601.
4. Amoura Z, Koutouzov S, Chabre H et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 76-84.
5. Trou w LA, Groeneveld TW, Seelen MA et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004; 114: 679-688.
6. Berden JH, Licht R, van Bruggen MC, Tax WJ. Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis. Curr Opin Nephrol Hypertens 1999; 8: 299-306.
7. Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 1977; 59: 90-96.
8. Roberts JL, Wyatt RJ, Schwartz MM, Lewis EJ. Differential characteristics of immune-bound antibodies in diffuse proliferative and membranous forms of lupus glomerulonephritis. Clin Immunol Immunopathol 1983; 29: 223-241.
9. Ohnishi K, Ebling FM, Mitchell B, Singh RR, Hahn BH, Tsao BP. Comparison of pathogenic and non-pathogenic murine antibodies to DNA: antigen binding and structural characteristics. Int Immunol 1994; 6: 817-830.
10. Ehrenstein MR, Katz DR, Griffiths MH et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int 1995; 48: 705-711.
11. Amoura Z, Piette JC, Bach JF, Koutouzov S. The key role of nucleosomes in lupus. Arthritis Rheum 1999; 42: 833-843.
12. Kallenberg CGM, Brouwer E, Weening JJ, Cohen Tervaert JW. Antineutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46: 1-15.
13. Savige J, Gillis D, Benson E et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999; 111: 507-513.
14. Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med 1995; 123: 925-932.
15. Hagen EC, Daha MR, Hermans J et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53: 743-753.
16. Rarok AA, Limburg PC, Kallenberg CGM. Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J Leuk Biol 2003; 74: 3-15.
17. Savage CO, Harper L, Holland M. New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 2002; 14: 15-22.
18. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955-963.
19. Pfister H, Ollert M, Frohlich LF et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004; 104: 1411-1418.
20. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004; 93: 398-401.
21. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CGM. Predictive value of rises in anti-double stranded DNA antibody levels for disease exacerbations in systemic lupus erythematosus: a longterm prospective study. Arthritis Rheum 1990; 33: 634-643.
22. Bootsma H, Spronk PE, ter Borg EJ et al. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation. Ann Rheum Dis 1997; 56: 661-666.
23. Isenberg DA, Dudeney C, Williams W et al. Measurement of anti-DNA antibodies: a reappraisal using five different methods. Ann Rheum Dis 1987; 46: 448-456.
24. Smeenk RJ, van den Brink HG, Brinkman K, Termaat RM, Berden JH, Swaak AJ. Anti-dsDNA: choice of assay in relation to clinical value. Rheumatol Int 1991; 11: 101-107.
25. Westman KW, Selga D, Bygren P et al. Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody. Kidney Int 1998; 53: 1230-1236.
26. Csernok E, Holle J, Hellmich B et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology 2004; 43: 174-180.
27. Boomsma MM, Stegeman CA, van der Leij MJ et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43: 2025-2033.
28. Damoiseaux JG, Slot MC, Vaessen M, Stegeman CA, Van Paassen P, Tervaert JW. Evaluation of a new fluorescent-enzyme immuno-assay for diagnosis and follow-up of ANCA-associated vasculitis. J Clin Immunol 2005; 25: 202-208.
29. Swaak AJ, Aarden LA, Statius van Eps LW, Feltkamp TE. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 1979; 22: 226-235.
30. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986; 45: 359-366.
31. Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2342-2349.
32. Bootsma H, Spronk PE, Derksen R et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595-1599.
33. Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CCM. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 2003; 62: 534-539.
34. Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Job T; LJP 394 Investigator Consortium. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1129-1137.
35. Cohen Tervaert JW, van der Woude FJ, Fauci AS et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Int Med 1989; 149: 2461-2465.
36. Cohen Tervaert JW, Huitema MG, Hené RJ et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709-711.
37. Egner W, Chapel HM. Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides. Clin Exp Immunol 1990; 82: 244-249.
38. Chan TM, Frampton G, Jayne DR et al. Clinical significance of anti-endothelial cell antibodies in systemic vasculitis: a longitudinal study comparing anti-endothelial cell antibodies and anti-neutrophil cytoplasm antibodies. Am J Kidney Dis 1993; 22: 387-392.
39. Kerr GS, Fleisher TA, Hallahan CW et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titre in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36: 365-371.
40. Davenport A, Lock RJ, Wallington T. Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescence test. Am J Nephrol 1995; 15: 201-207.
41. Kyndt X, Reumaux D, Bridoux F et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999; 106: 527-533.
42. Nowack R, Grab I, Flores-Suarez LF et al. ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transpl 2001; 16: 1631-1637.
43. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CGM. Association of nasal carriage of Staphylococcus aureus and higher relapse in Wegener's Granulomatosis. Ann Intern Med 1994; 120: 12-17.
44. Slot MC, Cohen Tervaert JW, Boomsma MM, Stegeman CA. A positive PR3-ANCA titre at switch to azathioprine therapy is associated with a disquieting relapse rate in ANCA-related vasculitis. Arthritis Rheum (Arthritis Care & Research) 2004; 51: 269-273.
45. Sanders JS, Huitema MG, Kallenberg CG, Stegeman CA. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology 2006; (Epub ahead of print).
46. Han WK, Choi HK, Roth RM et al. Serial ANCA titres: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 2003; 63: 1079-1085.
47. De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995; 25: 380-389.
48. Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. Q J Med 1995; 88: 127-133.
49. Ara J, Mirapeix E, Rodrigues R, Saurina A, Darnell A. Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. Nephrol Dial Transplant 1999; 14: 1667-1672.
50. Gisslen K, Wieslander J, Westberg G, Herlitz H. Relationship between anti-neutrophil cytoplasmic antibody determined with conventional binding and the capture assay, and long-term clinical course in vasculitis. J Intern Med 2002; 251: 129-135.
51. Birck R, Schmitt WH, Kaelsch IA, van der Woude FJ. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006; 47: 15-23.